The Delhi High Court’s sharp rebuke of Patanjali’s recent Chyawanprash commercial—where the ad reportedly labels competing products as “dhoka” (fraud)—has turned what looked like a routine advertising spat into a high‑stakes legal and reputational contest between two of India’s most prominent Ayurvedic brands.
Background
Patanjali’s 25‑second commercial, fronted by Baba Ramdev, promotes “Patanjali Special Chyawanprash” with an emphatic claim of being the
original and the
true power of Ayurveda. The ad includes the line that “most people are being duped in the name of Chyawanprash” and shows a scene with the words “chalo dhoka khao,” implying that competing chyawanprash products amount to deception. Dabur India, which long has dominated the chyawanprash segment, filed suit seeking an interim injunction, alleging defamation, disparagement, and unfair competition.
During the hearing, Justice Tejas Karia questioned Patanjali’s choice of language: while a company is free to claim superiority, the court observed, it cannot brand an entire category of licensed products as fraudulent. “You can say ‘inferior’—what’s the problem?—but you can’t call everyone ‘dhoka’,” the judge said, distinguishing permissible comparative marketing from what may amount to actionable disparagement.
The court reserved its order after hearing robust arguments from both sides. Dabur’s counsel argued the ad amounts to “generic disparagement” of the entire chyawanprash category and singled out Dabur by implication, given Dabur’s market prominence and the ad’s reference to other products being “made with 40 herbs.” Patanjali’s counsel defended the spot as
puffery—an advertising device using hyperbole to claim superiority without making disprovable factual statements.
Overview: what’s actually at stake
This dispute is not merely about a twenty‑five second advert. It sits at the intersection of four overlapping battlegrounds:
- Advertising law and commercial speech — how far does comparative advertising travel before it becomes unlawful disparagement?
- Regulatory compliance for Ayurvedic formulations — what claims are permissible on labels and in promotions for products regulated under the Drugs and Cosmetics Act framework and allied rules?
- Brand reputation and consumer trust — what are the commercial and perceptual consequences when a mass‑market ad alleges that the entire category is deceptive?
- Litigation strategy in FMCG competition — how market leaders and challengers use courts and regulators as commercial tools.
Each of these dimensions carries real commercial and legal consequences: injunctions and corrective advertising, regulator scrutiny of labeling claims, and reputational damage that can affect shelf placement and retail relationships.
Legal framework and standards
Comparative advertising vs. disparagement
Comparative advertising—saying “my product is better than yours”—is a widely accepted marketing tool. Courts generally allow
puffery and comparative claims so long as they do not make false statements of fact that mislead or defame competitors.
- Puffery is high‑level, subjective marketing speech (e.g., “the best”) that consumers are expected to treat as opinion.
- Disparagement occurs when statements are factual, false, and cause reputational harm to competitors or the category.
In regulated categories—like Ayurvedic products classed as ASU (Ayurvedic, Siddha, Unani) drugs—advertising claims face heightened scrutiny because consumers may rely on product claims for health and safety. The court’s instincts in this case reflect that traditional advertising‑law balancing: descriptive claims should be verifiable; subjective praise can be tolerated; categorical allegations of fraud can cross a legal line.
Statutory and regulatory contours for Ayurvedic products
Patanjali’s ad does several things that invite regulatory and legal attention:
- It asserts a specific ingredient count (“51 Ayurvedic herbs and saffron”) and uses the word “Special” before a classical preparation name.
- It suggests that other manufacturers are deceptive, which has potential civil and regulatory consequences.
Certain labeling and promotional restrictions apply to Ayurvedic and proprietary ASU drugs under the Drugs and Cosmetics Rules and related directives. Regulators expect accurate ingredient disclosure and avoid promotional terms that could mislead consumers about the product’s nature or compliance with authoritative Ayurvedic texts. Courts and consumer regulators therefore apply a stricter lens to claims for such products.
Rule referenced by complainant
Dabur’s plaint reportedly invokes a rule that bars deceptive labelling—commonly cited in these disputes—and challenges the use of “Special” in a product name. The precise legal mechanics of such rule‑based challenges are technical: the court considers whether the use of an adjective coupled with putative ingredient counts implies a therapeutic superiority or misleads consumers into thinking the product is a certified or unique classical formulation.
Note: specific statutory subsections and administrative advisories are often technical; where an advisory or rule is cited in litigation, the underlying government document or statutory text should be examined to confirm the scope of the restriction. Some claims in the filings refer to earlier government advisories about numerical claims such as “51 herbs”; that advisory is referenced in court filings and media reports, but the original administrative document should be consulted for any enforcement or compliance step.
What the ad claims — and what is disputed
Patanjali’s ad contains three interlocking claims that matter commercially and legally:
- Category disparagement: The ad suggests a large share of chyawanprash products constitute deception, by urging consumers not to “eat dhoka.”
- Ingredient superiority: It promotes Patanjali’s formulation as containing “51 Ayurvedic herbs and saffron,” implying a richer, more authentic composition than competitors.
- Brand positioning ("Special"): Patanjali uses the word “Special” in front of Chyawanprash, which Dabur contends is misleading for a classical preparation.
Dabur counters that these elements—taken together and distributed widely—amount to a campaign of generic disparagement against a class of licensed medicines and that the ingredient claim echoes earlier regulatory flags about unsubstantiated numerical claims on promotional material.
Patanjali’s defense rests on three pillars: the ad is
puffery (not a verifiable false assertion), the spots do not name Dabur explicitly (so no targeted defamation), and the language is meant to convey superiority rather than factual falsity.
Market context: why this matters commercially
- Dabur’s position: Dabur is the long‑standing market leader in the chyawanprash category and is widely identified with the 40‑herb formulation in many markets. Market‑share estimates routinely place Dabur in the dominant position, often quoted in the “~60%” range — this leadership amplifies any advertising claim that appears to attack the category because a broad claim against chyawanprash inevitably touches the leader’s reputation and shelf demand.
- Patanjali’s strategy: Patanjali’s growth playbook has been to attack perceived incumbents with nationalist and authenticity themes — leveraging a charismatic founder figure and price‑value positioning. That strategy works when consumers respond on trust and identity. It creates outsized visibility for any messaging that raises doubts about the category.
Practically, the commercial consequences are multiple: questioned legitimacy of competing products can depress sales, trigger retailer delisting requests, and prompt regulatory checks on labeling and ingredient claims. For a high‑margin but trust‑sensitive category like Ayurvedic supplements, perception moves the needle.
Courtroom dynamics and strategic legal points
Dabur’s legal posture — strengths and vulnerabilities
Strengths:
- Market leader status magnifies harm: if the ad creates category‑wide doubt, Dabur’s business exposure is substantial.
- Plausible claim of generic disparagement: statements that a “class” of lawful, licensed medicines are deceptive are prima facie capable of injuring reputations.
- Earlier regulatory and judicial findings: past orders requiring Patanjali to delete specific references make the current dispute part of a continuing pattern.
Vulnerabilities:
- Defamation law generally requires a targeted false factual statement about a plaintiff; generalized hyperbole is harder to prove.
- If Patanjali can show the ad is opinion‑based puffery, courts are less likely to enjoin it permanently.
- Litigation risk: long trials risk public airing of proprietary formulas and contested technical evidence.
Patanjali’s legal posture — strengths and vulnerabilities
Strengths:
- Puffery defense resonates in comparative advertising jurisprudence.
- Absence of an explicit mention of Dabur in the ad gives breathing room against defamation claims: courts often require a link to a specific plaintiff for defamation remedies.
- The brand’s public profile and rhetorical style mean many consumers read hyperbole into its marketing rather than literal deception claims.
Vulnerabilities:
- Courts have previously intervened in advertising disputes involving Patanjali; a pattern can persuade courts to be less tolerant.
- Specific ingredient claims (numerical herb counts, "Special" label) are verifiable and therefore risk being judged misleading if inconsistent with labelling or pharmacopoeial standards.
- Regulatory enforcement: if claims contravene the Drugs and Cosmetics Rules or consumer protection norms, advertising may be restrained independent of defamation law.
Broader implications: advertising practice, regulator posture, and market signalling
For advertisers and marketing teams
- Comparative ads can be effective but must be carefully scripted in regulated categories. Avoid categorical allegations of fraud across a class of licensed medicines.
- Distinguish opinion from fact. Phrases that can be proven false (ingredient counts, specific foreign assertions) must be defensible with documentation.
- Pre‑launch legal review should be mandatory for claims that reference classical texts, ingredient numbers, or regulatory language.
For regulators and courts
- The case underlines that courts are balancing free commercial speech with consumer protection—particularly in health‑adjacent categories where consumers are vulnerable to misleading claims.
- Agencies enforcing labelling rules should publish clear guidance on allowed descriptors (e.g., “special”, “original”, “improved”) relative to classical formulations to reduce uncertainty and litigation.
For investors and retailers
- Retailers should treat regulatory and litigation exposure as a supply‑chain risk: advertising that prompts regulatory action can trigger delisting or inventory repricing.
- Investors in consumer brands must factor in reputational volatility from high‑profile advertising disputes; short‑term gains from attention can be offset by long‑term trust damage.
Practical checklist for brands operating in regulated health-adjacent categories
- Conduct a claim audit: list every factual claim (ingredient counts, efficacy statements) and map evidence (lab tests, supplier certificates, pharmacopoeial references).
- Distinguish branding from medical claims: label adjectives (“special”) should not imply therapeutic uniqueness unless supported by evidence and permissible under regulation.
- Use neutral comparative language: “contains X herbs” is factual; “others are fraud” is not. Prefer “contains more of X” or “formulated with X” where safety and evidence exist.
- Obtain legal sign‑off: marketing launch gates must include regulatory counsel and product‑quality certification.
- Prepare a rapid response plan: if a competitor files suit or regulator queries arise, have a communications and legal playbook ready.
Risks and likely outcomes
- Short term: an interim order restraining the ad or compelling edits is a likely outcome given the court’s skepticism about categorical “fraud” claims delivered by a figure of public authority. Courts often prefer modified injunctive relief (delete specific lines, tone down language) rather than permanent bans at the interlocutory stage.
- Medium term: regulatory agencies may request labelling audits and substantiation for numerical or superiority claims. That could lead to corrective labels, advertisements, or fines if non‑compliance is found.
- Long term: court rulings in this dispute will shape the permissible boundaries of comparative advertising in India’s regulated product categories, making future campaigns more cautious and compliance‑centric.
Critical analysis: strengths and blind spots in the case
Strengths of Dabur’s position
- Credible claim of injury: a mass‑broadcast advertisement that suggests the entire category is deceptive plainly risks consumer confidence and sales.
- Regulatory hooks: numerical ingredient claims and the use of “Special” open the door to straightforward regulatory scrutiny.
- Moral intensity: courts are sensitive when a public figure’s statement could mislead health‑conscious consumers.
Risks and blind spots for Dabur
- Proving specific falsity: Dabur must show the ad’s core assertions are verifiably false and specifically injurious to its brand beyond general competitive noise.
- Public perception: aggressively suing a challenger risks making Dabur appear litigious; some consumers might interpret litigation as an attempt to suppress opinion.
Strengths of Patanjali’s position
- Puffery defense: courts long have tolerated subjective superiority claims as non‑actionable if the statements are rhetorical and not factually specific.
- Narrative resonance: the ad plays to a potent authenticity story that can mobilize existing brand loyalty.
Risks and blind spots for Patanjali
- Regulatory exposure: ingredient claims and labeling descriptors are verifiable; any mismatch with label claims or pharmacopoeial standards invites regulatory penalties independent of defamation suits.
- Reputational hazard: public statements that accuse an entire class of products of fraud can backfire if courts or regulators side with competitors.
What this means for consumers and the category
- Consumers should treat bold health claims and categorical assertions with skepticism and look for verifiable facts: ingredient lists, batch testing, and manufacturer certificates.
- The dispute signals a marketplace maturing toward legal clarity: brands that make evidenceable claims and maintain quality documentation will be shielded; those that rely on rhetorical attacks will sooner or later face scrutiny.
Conclusion
The Patanjali–Dabur clash over a Chyawanprash commercial is a modern case study in how advertising, law, regulation, and brand reputation collide in the age of viral marketing. The Delhi High Court’s pointed observation—
you can say ‘inferior’, but you cannot call everyone ‘dhoka’—captures the practical rule that will likely guide outcomes: marketers may sing their own praises, but they cannot declare an entire, regulated category fraudulent without risking judicial and regulatory correction.
For brand marketers, the practical lesson is simple yet profound: in regulated categories anchored in public health and traditional knowledge, persuasive storytelling must be matched by rigorous substantiation. For litigators and regulators, the case will help refine the boundary between permissible puffery and impermissible disparagement. For consumers, the dispute is a reminder to look past rhetorical claims and seek the underlying evidence that supports health‑related marketing.
Ultimately, the court’s reserved verdict will do more than adjudicate a single ad; it will send signals to an industry where authenticity, regulation, and reputation are interlinked—and where one provocative phrase can prompt a multi‑front contest in courtrooms, regulator offices, and consumer perception.
Source: Storyboard18
“You can’t call everyone ‘dhoka’”: Delhi HC pulls up Patanjali over Chyawanprash ad